Article and Video CATEGORIES
Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone and Former Chief Fellow @MayoClinic in Rochester, Minnesota. In addition to her dedication to her patients as a provider, Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association.
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and how it affects the community.
This 2 part series, presented in Spanish for the Latino community, covers information relating to the following topics. Please scroll down for part 2 of this important series.
What is coronavirus?
¿Qué es el COVID-19?
What are the common symptoms?
¿Cuales son los síntomas mas comunes de la infección COVID-19?
How is it contracted, and how can it be prevented?
¿Qué puedo hacer para evitar contraer COVID-19?
Who is at risk, and are people with cancer at higher risk?
¿Las personas con cáncer deberían tomar precauciones especiales?
Does the risk of exposure change my treatment for cancer?
¿Puede el riesgo de exposición al virus cambiar mi tratamiento para el cáncer? ¿Como va a cambiar mi interacción con mi doctor del cáncer?
What happens if I get coronavirus and have cancer?
¿Que pasa si me contraigo el coronavirus?
¿Puedo seguir con mi tratamiento para el cáncer?
I hear about treatments: are these now established as effective?
¿Hay tratamientos para COVID-19?
¿Puede la inmunoterapia protegerme en contra del COVID-19?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…